4DMedical Raises $100M to Scale U.S. Lung Imaging Tech
Event summary
- 4DMedical secured $100M+ in institutional funding to expand U.S. operations and R&D for its CT:VQ™ lung imaging software.
- CT:VQ™, FDA-cleared in 2025, was adopted by four elite U.S. medical centers within four months of clearance.
- Funding will support commercial expansion, customer success initiatives, and operational scaling across U.S. health systems.
- Post-raise, 4DMedical's pro forma cash position exceeds $130M, bolstering its U.S. growth strategy.
The big picture
4DMedical's funding reflects growing demand for advanced lung imaging tools that provide functional insights beyond traditional diagnostics. The rapid adoption of CT:VQ™ by top-tier medical centers underscores a shift toward data-driven respiratory care, positioning 4DMedical to capitalize on the $100M+ investment to solidify its market dominance. The company's SaaS model and strategic partnerships further streamline its path to scaling in the U.S. healthcare landscape.
What we're watching
- Adoption Pace
- How quickly 4DMedical can scale CT:VQ™ beyond early adopters to broader U.S. health systems.
- Technology Leadership
- Whether 4DMedical can sustain its R&D lead in software-based lung imaging amid competitive pressures.
- Partnership Impact
- The role of strategic partnerships, like Philips, in accelerating CT:VQ™ integration and market penetration.
Related topics